Mark C Schneyer's most recent trade in Acadia Pharmaceuticals Inc was a trade of 2,000 Common Stock done at an average price of $25 . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 May 2025 | 2,000 | 62,130 (0%) | 0% | 25 | 50,000 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark Schneyer C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 6,815 | 13,630 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | C. Mark Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 6,815 | 66,271 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | C. Mark Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 01 May 2025 | 3,498 | 62,773 (0%) | 0% | 14.6 | 51,071 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2025 | 5,275 | 5,276 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2025 | 5,275 | 62,164 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.82 per share. | 05 Apr 2025 | 2,708 | 59,456 (0%) | 0% | 14.8 | 40,133 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 110,761 | 110,761 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 32,552 | 32,552 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 6,178 | 60,060 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 6,178 | 18,536 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 24 Mar 2025 | 3,171 | 56,889 (0%) | 0% | 17.1 | 54,066 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 1,353 | 54,655 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 1,353 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 23 Feb 2025 | 773 | 53,882 (0%) | 0% | 20.0 | 15,429 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 16.81 per share. | 17 Nov 2024 | 10,259 | 53,302 (0%) | 0% | 16.8 | 172,454 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 63,561 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 53,648 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 13,629 | 53,468 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.28 per share. | 16 Aug 2024 | 9,733 | 43,735 (0%) | 0% | 15.3 | 148,720 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,275 | 39,839 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2024 | 1,893 | 35,539 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2024 | 1,893 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.79 per share. | 08 Jun 2024 | 975 | 34,564 (0%) | 0% | 14.8 | 14,420 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 6,814 | 20,445 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 6,814 | 35,556 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 01 May 2024 | 3,503 | 32,053 (0%) | 0% | 16.9 | 59,341 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 5,275 | 10,551 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 5,275 | 31,458 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 2,716 | 28,742 (0%) | 0% | 17.9 | 48,535 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 80,564 | 80,564 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 24,714 | 24,714 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 10,550 | 31,617 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.90 per share. | 25 Mar 2024 | 5,434 | 26,183 (0%) | 0% | 17.9 | 97,269 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 1,353 | 21,839 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark Schneyer C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 1,353 | 1,353 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 23 Feb 2024 | 772 | 21,067 (0%) | 0% | 24.7 | 19,045 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 21 Aug 2023 | 10,000 | 15,682 (0%) | 0% | 29.0 | 289,970 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 1,893 | 1,893 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 1,893 | 23,798 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 08 Jun 2023 | 974 | 22,824 (0%) | 0% | 25.0 | 24,369 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 17 May 2023 | 15,310 | 21,905 (0%) | 0% | 22.5 | 344,475 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 37,215 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 24,782 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 24,782 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 22,346 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 89,936 | 89,936 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 27,259 | 27,259 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 5,275 | 9,393 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 5,275 | 15,826 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 05 Apr 2023 | 1,916 | 7,477 (0%) | 0% | 18.2 | 34,795 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 1,353 | 4,695 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 1,353 | 2,706 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 23 Feb 2023 | 577 | 4,118 (0%) | 0% | 18.8 | 10,836 | Common Stock |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 72,414 | 72,414 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 21,101 | 21,101 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 1,352 | 4,059 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 1,352 | 2,655 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Mark C. Schneyer | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.80 per share. | 23 Feb 2022 | 553 | 2,102 (0%) | 0% | 23.8 | 13,161 | Common Stock |